Al Roker, Type 2 Diabetes, and Insulin: What His Treatment Would Cost Someone Without a Celebrity Salary

What Al Roker Has Said About His Diabetes and Weight History

Al Roker has not hidden his health journey. He has discussed Type 2 diabetes, weight gain, and his 2002 gastric bypass surgery in multiple televised interviews and in his own public statements over more than two decades.

In his 2012 book "Never Goin' Back," Roker wrote candidly about regaining weight after bariatric surgery and the ongoing work required to maintain metabolic health. He has acknowledged on-air that managing blood sugar remains part of his daily life. These are his words, not inference.

What He Has Not Disclosed

Roker has not publicly named specific medications he takes for diabetes. Any discussion of particular drug classes in this article is therefore clinical inference based on:

1. The standard of care for T2D in a patient with prior bariatric surgery.
2. Current American Diabetes Association (ADA) 2024 Standards of Care guidelines.
3. His publicly stated history of significant weight loss followed by partial weight regain.

Where inference is used, it is labeled as such.

Why Bariatric History Matters Clinically

Gastric bypass surgery produces T2D remission in roughly 50 to 80% of patients in the first year post-surgery. The STAMPEDE trial (N=150) found that 42% of bariatric surgery patients achieved an HbA1c of 6.0% or below at 5 years, compared with 9% in the intensive medical therapy group (Schauer et al., NEJM 2017). However, remission is not permanent for everyone. Weight regain, which Roker has acknowledged, is associated with T2D recurrence in a meaningful proportion of patients.

This clinical background explains why a patient like Roker, two decades out from bariatric surgery, may still require pharmacological management even after an initial period of remission.

The Drug Classes Most Likely Involved in His Care

Based on ADA 2024 Standards of Care and the clinical profile of a T2D patient with a history of bariatric surgery and cardiovascular risk factors consistent with his age (70 years old as of 2025), the following drug classes represent the standard-of-care options most commonly prescribed. This is clinical inference, not confirmed reporting.

Metformin

Metformin remains the most prescribed oral glucose-lowering agent in the United States. The ADA 2024 Standards of Care state: "Metformin remains a cost-effective, well-tolerated first-line agent and may be continued when added to other glucose-lowering therapies" (ADA, Diabetes Care 2024).

For patients with prior gastric bypass, absorption of metformin extended-release may be altered, so immediate-release formulations are generally preferred. Generic metformin costs $4, $10 per month at Walmart, Costco, and most major US pharmacy chains.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (GLP-1 RAs) are now a cornerstone of T2D management for patients who need weight management alongside glycemic control, which describes many post-bariatric patients who have experienced weight regain. Semaglutide (Ozempic, 0.5 to 2 mg weekly subcutaneous injection) is the most widely prescribed GLP-1 RA in the US as of 2024.

The SUSTAIN-6 trial (N=3,297) showed that once-weekly semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 26% compared with placebo in patients with T2D and established cardiovascular disease or high CV risk (Marso et al., NEJM 2016). Given Roker's age and cardiac history (he underwent emergency surgery for internal bleeding and other hospitalizations in 2022), a GLP-1 RA with demonstrated cardiovascular benefit would align with ADA guidelines for his risk profile. This remains inference.

SGLT-2 Inhibitors

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors such as empagliflozin (Jardiance) or dapagliflozin (Farxiga) are recommended by ADA 2024 guidelines as preferred add-ons for T2D patients with established heart failure or chronic kidney disease. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% versus placebo in T2D patients with high CV risk (Zinman et al., NEJM 2015).

Whether Roker takes an SGLT-2 inhibitor is not publicly known.

Insulin

Insulin therapy is typically reserved for T2D patients who fail to achieve glycemic targets on oral agents and GLP-1 RAs, or those with very high HbA1c at diagnosis. Post-bariatric patients sometimes require insulin during periods of metabolic stress or recurrence.

The most commonly prescribed basal insulin in the US is insulin glargine. Both the originator product (Lantus) and biosimilar versions (Basaglar, Rezvoglar) are available. Tresiba (insulin degludec) is another long-acting option with a flatter peak profile.

Real-World Cost Breakdown for a Non-Celebrity American

This is where the clinical picture collides with economic reality. The same regimen a high-earning public figure accesses through premium insurance or direct cash pay looks very different on a median American household income of approximately $74,580 (US Census Bureau 2023).

Metformin: The Affordable Option

Generic metformin 500 to 1,000 mg twice daily costs:

• $4, $10/month at Walmart, Costco, Kroger, and Walgreens with GoodRx or discount programs.
• $0/month for most insured patients, as it is on virtually every formulary Tier 1.

Cost is not a barrier for metformin. This drug has been off-patent since the 1990s and is one of the most accessible medications in American pharmacy.

GLP-1 Receptor Agonists: The Expensive Middle

Semaglutide (Ozempic) carries a US list price of approximately $936 per month for a 1 mg dose as of late 2024, according to Novo Nordisk's published pricing. Most commercially insured patients pay $25, $100/month with prior authorization. Uninsured patients face the full list price unless they qualify for the Novo Nordisk Patient Assistance Program, which caps cost at $99/month for eligible patients earning below 400% of the federal poverty level.

Tirzepatide (Mounjaro, Eli Lilly), a dual GIP/GLP-1 agonist with even stronger glycemic and weight-loss data from the SURPASS-2 trial (N=1,879, producing 2.3% greater HbA1c reduction versus semaglutide at 40 weeks) (Frías et al., NEJM 2021), lists at approximately $1,023/month.

For a T2D patient on a GLP-1 RA without insurance, the annual drug cost alone runs $11,000, $12,000.

SGLT-2 Inhibitors: Mid-Range With Good Formulary Access

Empagliflozin (Jardiance) lists at approximately $600/month. Most commercial insurers cover it at Tier 2 or Tier 3, meaning copays of $35, $150/month are common. A 2022 analysis in JAMA Network Open found that out-of-pocket costs for SGLT-2 inhibitors were a significant adherence barrier for low-income T2D patients even with insurance, with 18% reporting cost-related non-adherence.

Insulin: A Crisis of Affordability and a Partial Fix

Insulin prices in the United States have been the subject of Senate hearings, class-action suits, and federal legislation. Before the Inflation Reduction Act (IRA) of 2022, some T2D patients on Medicare paid over $300/month for insulin.

Current field as of 2025:

• Medicare beneficiaries pay a maximum of $35/month per insulin product under the IRA out-of-pocket cap (CMS.gov).
• Commercially insured patients typically pay $35/month through manufacturer copay programs (Eli Lilly's Insulin Value Program, Novo Nordisk's $99 cap program, Sanofi's Insulins Valyou program).
• Uninsured patients face list prices of $300, $500/month for brand-name glargine products. Biosimilar insulin glargine (Rezvoglar, Eli Lilly) launched in 2023 at $92/vial, roughly 78% below the Lantus list price.

A 2019 JAMA Internal Medicine study (N=199 insulin-using T2D adults) found that 25% of patients reported rationing insulin due to cost, a practice associated with diabetic ketoacidosis hospitalizations and preventable deaths (Herkert et al., JAMA Intern Med 2019).

The Full Monthly Regimen Cost: A Side-by-Side

| Medication | Uninsured List Price | With Good Commercial Insurance | Medicare (2025) | |---|---|---|---| | Metformin 1,000 mg BID | $4, $10 | $0 | $0 | | Semaglutide 1 mg/wk (Ozempic) | ~$936 | $25, $100 | $35, $100 | | Empagliflozin 10 mg/day (Jardiance) | ~$600 | $35, $150 | $35, $75 | | Insulin glargine biosimilar | ~$92/vial | $35 | $35 (IRA cap) | | Estimated monthly total (full regimen) | $1,630, $1,640 | $95, $285 | $105, $210 |

This table uses 2024-2025 US pricing and does not include monitoring supplies (CGM, test strips) or physician visit costs.

What Current ADA Guidelines Actually Recommend

The ADA 2024 Standards of Care provide a weight-of-evidence framework for T2D pharmacotherapy. The document is 280 pages, but the core algorithm for most T2D patients is summarized in three tiers.

First-Line Therapy

Lifestyle modification plus metformin for patients without compelling indications for a specific drug class. The ADA states: "For patients with Type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular or kidney benefit is recommended independent of HbA1c" (ADA Standards of Care 2024, Section 9).

When GLP-1 RAs Take Priority

For patients who need weight loss as part of their T2D management, which includes post-bariatric patients with weight regain, GLP-1 RAs are elevated to preferred status. The ADA also now recognizes that GLP-1 RAs may themselves substitute for bariatric surgery in some patients, though this remains an area of ongoing research.

Insulin as a Later Option

Basal insulin is added when HbA1c remains above 10% or symptoms of hyperglycemia are present despite dual oral/injectable therapy. The ADA target HbA1c for most non-pregnant adults is below 7.0%, with individualization allowed for older adults or those with hypoglycemia unawareness.

Bariatric Surgery and T2D Remission: What the Evidence Shows

Al Roker's 2002 gastric bypass is clinically relevant not just as biography but as a window into what bariatric surgery does and does not guarantee for long-term T2D control.

Short-Term Remission Is Real and Documented

Roux-en-Y gastric bypass (RYGB) produces T2D remission rates of 50 to 80% at one year. The STAMPEDE trial's 5-year follow-up (Schauer et al., NEJM 2017) remains the landmark RCT in this space. At 5 years, 29% of RYGB patients maintained an HbA1c of 6.0% or below versus 5% of intensive medical therapy patients (Schauer et al., NEJM 2017).

Weight Regain Reverses Some Benefits

A 2020 analysis in Obesity Surgery (N=782) found that patients who regained more than 25% of their maximum lost weight had a 3.4-fold higher odds of T2D recurrence at 10 years. Weight regain after bariatric surgery is common: a 2018 JAMA Surgery study found that patients regained an average of 29% of their maximal lost weight by 5 years post-surgery.

Post-Bariatric GLP-1 RA Use Is Growing

GLP-1 RAs are increasingly used in post-bariatric patients to manage weight regain and T2D recurrence. A 2022 review in Obesity Reviews noted that semaglutide produced meaningful additional weight loss (8 to 12%) in post-bariatric patients who had regained weight. This is precisely the clinical scenario where a physician treating a patient with Roker's profile, based on publicly available information, would consider a GLP-1 RA. This remains inference.

The Affordability Gap: Why Celebrity Access Differs From Average-American Access

Al Roker is a high-income public figure who has worked for NBC for over 40 years. He almost certainly has premium employer-sponsored health insurance. This matters for T2D management in concrete ways.

Three Access Tiers for the Same T2D Regimen

Tier 1 (High-income, premium employer insurance or direct cash pay): A patient can access any drug on the market, any brand, without prior authorization delays. Out-of-pocket costs are typically $0, $100/month for an entire regimen. Continuity of care is high. Endocrinology specialist access is immediate.

Tier 2 (Middle-income, ACA marketplace or standard employer plan): Most guideline-recommended drugs are accessible, but prior authorization for GLP-1 RAs and SGLT-2 inhibitors is common. Average approval timelines run 3 to 14 days, with some requiring step therapy (trying metformin alone first). Copays of $50, $300/month are possible. Formulary switches between plan years can disrupt therapy.

Tier 3 (Uninsured or underinsured, income above Medicaid threshold but below ACA subsidy sweet spot): This population, roughly 25.6 million Americans according to CDC National Health Interview Survey 2023 data, faces list-price drugs. The $936/month Ozempic price is out of reach for most. Patient assistance programs exist but require annual recertification and income verification. Insulin rationing, documented at 25% prevalence in one JAMA Internal Medicine sample, is a real and sometimes fatal consequence.

What Changes With the IRA and State-Level Action

The Inflation Reduction Act capped Medicare insulin costs at $35/month. It did not cap insulin prices for commercial or uninsured patients. Several states, including California and Colorado, have enacted their own insulin price caps at $35 or $100/month for residents regardless of insurance status. GLP-1 RAs remain largely unaddressed by federal or state price controls.

The CMS announced in 2024 that it would negotiate prices for 10 drugs under the IRA's drug price negotiation authority, with results taking effect in 2026. Drugs selected in the first round were primarily small-molecule drugs, not biologics or GLP-1 RAs.

Monitoring: CGM and HbA1c Testing Costs

Medication is only one part of T2D management costs. Continuous glucose monitoring (CGM) has become standard-of-care for insulin-using T2D patients and is increasingly used even in non-insulin-treated T2D.

The Dexcom G7 retails at approximately $349/month without insurance. FreeStyle Libre 3 (Abbott) runs approximately $108/month. Medicare covers CGM for insulin-using T2D patients, but commercial coverage varies. An HbA1c lab test costs $10, $30 with a discount lab, versus $0, $20 with most insurance.

For a non-insured T2D patient trying to replicate the monitoring standard that a well-resourced patient receives, total annual monitoring costs could add $1,300, $4,200/year to the drug costs above.